David R. Bauer

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0 billion aggregate principal amount of its 2.250% notes due 2050…

Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and pre-funded warrants offering by Aeglea, including the full exercise…

Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of $1.5 billion principal amount of 2.250% senior notes due 2030…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million aggregate principal amount of its 0.375% convertible senior notes due…

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by CytomX Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million…

Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 2,300,000 shares of its common stock. The common stock is listed on the…

Davis Polk advised the underwriters in connection with an initial public offering of 16,100,000 shares of common stock of Revolution Medicines, Inc. at $17.00 per share (which includes the…

Davis Polk advised the underwriters in connection with the $148.5 million public offering of ordinary shares by Theravance Biopharma, Inc. Theravance Biopharma’s ordinary shares…

Davis Polk advised the underwriters in connection with a $75 million public offering of common stock by RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on the …